arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Rein Therapeutics, Inc.

RNTX

$0.61 ▼ -0.06 (-9.21%) at close

12 Visible periods

22 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Rein Therapeutics, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $15.5M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -236.4% ↘

FCF / Share $-0.76 ↗

Trailing P/E —

Price / Book 1.0x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

12-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-49.87M

↑ +20.7% —

FCF / Share Free cash flow per share

$-0.76

↑ +38.8% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Dividend History

Dividend / share · sourced from SEC filings

$0.00 Latest / share

FY 2014

FY 2015

$0.00

FY 2016

$0.00

FY 2017

$0.00

FY 2018

$0.00

FY 2019

$0.00

FY 2020

$0.00

FY 2021

$0.00

FY 2022

$0.00

FY 2023

$0.00

FY 2024

$0.00

FY 2025

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
EPS Growth YoY (%)	44.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-2.6% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	43.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-2.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	20.7% Good ↑ Good Improving Year-over-year change in net income	-299.7% Weak ↓ Weak Declining Year-over-year change in net income	42.4% Excellent ↑ Excellent Improving Year-over-year change in net income	-4.5% Weak ↓ Weak Declining Year-over-year change in net income	-23.7% Weak ↓ Weak Declining Year-over-year change in net income	28.0% Excellent ↑ Excellent Improving Year-over-year change in net income	6.9% Fair ↑ Fair Improving Year-over-year change in net income	-39.6% Weak ↓ Weak Declining Year-over-year change in net income	-24.7% Weak Weak Year-over-year change in net income	-40.7% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	38.8% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	71.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	21.4% Good Good Year-over-year change in free cash flow	-1.7% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
FCF / Net Income (x)	0.39x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.35x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.26x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.03x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Return on Invested Capital (%)	-236.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-94.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-186.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-117.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-47.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-133.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-147.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-128.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-38.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	12.8% Good Good Return earned on debt + equity capital invested Optimal: > 10%	10.8% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-209.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-104.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-15.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-125.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-54.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-125.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-113.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-105.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-43.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-82.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-294.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-2065%)	-115.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-871%)	-228.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1623%)	-146.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1078%)	-59.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-497%)	-174.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1260%)	-183.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1320%)	-161.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1173%)	-47.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-415%)	16.2% Good Good Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+8%)	13.7% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-9%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Net Debt (USD)	$-3.21M	$-12.87M	$-17.31M	$-5.19M	$-3.60M	$-7.05M	$-5.31M	$-10.63M	$-11.86M	$-20.71M	$-3.77M	$-6.21M

📊 What does each share earn? 8 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Revenue per Share (USD)	$0.00	$0.00	$0.00	$0.00	$0.00	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-1.96	$-3.51	$-3.42	$-6.02	$-5.89	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-0.76	$-1.24	$-4.31	$-5.48	$-5.38	—	—	—	—	—	—	—
Dividend per Share (USD)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	—	—
Book Value per Share (USD)	$0.61	$2.51	$1.41	$4.10	$9.69	$5.55	$11.54	$26.58	$64.92	$-5.17K	—	—
Tangible Book Value per Share (USD)	$-0.11	$0.27	$-16.10	$4.10	$9.69	$5.55	$11.54	$26.58	$64.92	$-5.17K	—	—
Basic Weighted Avg Shares (shares)	25.44M	17.94M	4.60M	4.54M	4.44M	—	—	—	—	—	—	—
Dividend Payout Ratio (%)	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Working Capital (USD)	$-1.85M	$7.91M	$13.88M	$18.49M	$43.67M	$12.37M	$13.71M	$16.41M	$46.95M	$17.00M	—	—
Total Equity (USD)	$16.92M	$54.39M	$6.89M	$18.62M	$43.90M	$12.16M	$16.05M	$19.60M	$47.80M	$-111.81M	$-94.32M	$-82.04M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	—
Depreciation Expense (USD)	$1.00K	$63.00K	$119.00K	$169.00K	$121.00K	$163.00K	$155.00K	$218.00K	$129.00K	$232.00K	$325.00K	—
Net Income, GAAP (USD)	$-49.87M	$-62.88M	$-15.73M	$-27.33M	$-26.16M	$-21.16M	$-29.37M	$-31.55M	$-22.60M	$-18.12M	$-12.88M	—
Operating Cash Flow (USD)	$-19.36M	$-22.29M	$-19.81M	$-24.86M	$-23.75M	$-20.48M	$-26.47M	$-27.93M	$-20.53M	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 12 years · 43 quarters

Rein Therapeutics, Inc.

Analytical Summary

12-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Dividend History

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare RNTX with peers